海利生物(603718.SH)擬向開曼藥明海德等比例增資 建設愛爾蘭疫苗項目
格隆匯5月13日丨海利生物(603718.SH)公佈,公司與WuXi Biologics (Cayman) Inc.(藥明生物技術有限公司,以下簡稱藥明生物)擬同比例認購開曼藥明海德增發的股份,其中公司按持股比例30%的最高總認購價為4050萬美元(按當日匯率摺合人民幣約2.61億元),將以公司自有資金支付。
標的公司為從事人用疫苗合同定製研發生產(CDMO)業務的持股平台公司,本次增資主要用於其愛爾蘭疫苗項目的建設,該項目涉及的生產基地仍在建設過程中,因此預計短期內不會產生盈利,對公司業績的影響暫無法預計,存在較大的不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.